Effectiveness of infiltration with buffered 4% articaine hydrochloride with 1:200,000 epinephrine for pulp therapy in primary second mandibular molar and permanent first mandibular molar
Phase 3
- Conditions
- Health Condition 1: K040- Pulpitis
- Registration Number
- CTRI/2022/07/044085
- Lead Sponsor
- Dr Sushmitha P
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. American society of Anaesthesiologists (ASA) 1 children.
2. Children reporting to the department with vital teeth requiring access opening as a part of pulp treatment in primary mandibular second molar or permanent mandibular first molar under local anaesthesia
Exclusion Criteria
1. Frankl definitely negative children.
2. Children with history of allergy to local anesthesia
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare and evaluate the effectiveness of supraperiosteal injection of buffered 4% articaine hydrochloride and 4% articaine hydrochloride with 1:200,000 epinephrine for pulpal procedures in primary mandibular second molars and permanent mandibular first molars using Face, Legs, Activity, Cry, Consolability Scale . <br/ ><br>Timepoint: 1 year
- Secondary Outcome Measures
Name Time Method To evaluate for any side effects of 4% buffered articaine solution on administration of supraperiosteal injection.Timepoint: 1 year
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does buffered 4% articaine with epinephrine's sodium channel blockade mechanism compare to non-buffered formulations in mandibular molar pulpitis?
What is the comparative anesthetic efficacy of supraperiosteal buffered articaine vs standard lidocaine in primary and permanent mandibular molar pulp therapy?
Which biomarkers predict response to epinephrine-containing articaine in pediatric vs adult dental pulpitis patients?
What are the adverse event profiles of buffered articaine with epinephrine in mandibular molar pulp therapy for CTRI/2022/07/044085?
How do combination approaches with articaine and adjuvants like felypressin enhance anesthetic duration in dental pulpitis management?